Literature DB >> 18607689

Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin.

David J Schneider1, Burton E Sobel.   

Abstract

To determine whether a regimen of aspirin pretreatment, bivalirudin during the procedure and clopidogrel (600 mg) immediately after percutaneous coronary intervention (PCI) was associated with platelet activation during and shortly after (1 and 2 h) PCI, we characterized platelet function in 10 patients with the use of flow cytometry in the absence of agonist and in response to thrombin (10 nM), ADP (1 microM), the collagen-mimetic convulxin (5 ng/ml), and platelet activating factor (10 nM). Activation of platelets in peripheral blood was rare (<0.5% of platelets) before, during and after PCI. Platelet reactivity in response to each of the agonists was lower after the PCI compared with that in blood taken before the PCI. Accordingly, platelet activation and platelet reactivity were not increased after elective PCI when patients were treated during the procedure with aspirin and bivalirudin and immediately after the procedure with a 600 mg loading dose of clopidogrel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18607689     DOI: 10.1007/s11239-008-0250-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  18 in total

1.  Contributions of young platelets and of previously activated platelets to platelet reactivity in patients with coronary artery disease.

Authors:  David J Schneider; Chris E Holmes; Heidi S Taatjes-Sommer; Burton E Sobel
Journal:  Thromb Res       Date:  2007-08-01       Impact factor: 3.944

2.  Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation.

Authors:  David J Schneider; Friederike Keating; Burton E Sobel
Journal:  Coron Artery Dis       Date:  2006-08       Impact factor: 1.439

3.  Platelet reactivity in coronary ostial blood: a reflection of the thrombotic state accompanying plaque rupture and of the adequacy of anti-thrombotic therapy.

Authors:  S S Kabbani; M W Watkins; P A Holoch; E F Terrien; B E Sobel; D J Schneider
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

4.  Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.

Authors:  Soochong Kim; Carolyn Foster; Anna Lecchi; Todd M Quinton; Dina M Prosser; Jianguo Jin; Marco Cattaneo; Satya P Kunapuli
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

5.  Increased platelet reactivity in unstable angina patients is not related to C-reactive protein levels.

Authors:  Alfonso Sestito; Gregory Angelo Sgueglia; Antonella Spinelli; Eliano Pio Navarese; Fabio Infusino; Filippo Crea; Gaetano Antonio Lanza
Journal:  Platelets       Date:  2006-08       Impact factor: 3.862

6.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Authors:  A Michael Lincoff; John A Bittl; Robert A Harrington; Frederick Feit; Neal S Kleiman; J Daniel Jackman; Ian J Sarembock; David J Cohen; Douglas Spriggs; Ramin Ebrahimi; Gadi Keren; Jeffrey Carr; Eric A Cohen; Amadeo Betriu; Walter Desmet; Dean J Kereiakes; Wolfgang Rutsch; Robert G Wilcox; Pim J de Feyter; Alec Vahanian; Eric J Topol
Journal:  JAMA       Date:  2003-02-19       Impact factor: 56.272

7.  Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential.

Authors:  R C Becker; F A Spencer; Y Li; S P Ball; Y Ma; T Hurley; J Hebert
Journal:  J Am Coll Cardiol       Date:  1999-10       Impact factor: 24.094

8.  Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group.

Authors: 
Journal:  Lancet       Date:  1990-10-06       Impact factor: 79.321

9.  Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions.

Authors:  M W Watkins; P A Luetmer; D J Schneider; W T Witmer; P T Vaitkus; B E Sobel
Journal:  Cathet Cardiovasc Diagn       Date:  1998-07

10.  Gly-Pro-Arg-Pro modifies the glutamine residues in the alpha- and gamma-chains of fibrinogen: inhibition of transglutaminase cross-linking.

Authors:  K E Achyuthan; J V Dobson; C S Greenberg
Journal:  Biochim Biophys Acta       Date:  1986-08-15
View more
  2 in total

Review 1.  Bivalirudin: in patients with ST-segment elevation myocardial infarction.

Authors:  Monique P Curran
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

2.  Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention.

Authors:  Carey Kimmelstiel; Ping Zhang; Navin K Kapur; Andrew Weintraub; Barath Krishnamurthy; Vilma Castaneda; Lidija Covic; Athan Kuliopulos
Journal:  Circ Cardiovasc Interv       Date:  2011-03-01       Impact factor: 6.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.